

# CHANGING THE LANDSCAPE IN GI

*Going beyond to advance treatments for acid-related disorders*

We are building a leading gastrointestinal-focused pharmaceutical company to improve the lives of people suffering from GI diseases.

Phathom is developing vonoprazan, an investigational potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to be the first gastric, anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.

Our development programs build upon a solid foundation of studies in over 8,000 patients around the world. Vonoprazan\* is currently approved in Japan and numerous other countries in Asia and Latin America.

## Quick Facts

>70 Employees

Founded May 12, 2019

IPO October 29, 2019

\$PHAT on NASDAQ

## ABOUT US

### Phathom Pharmaceuticals, Inc.

100 Campus Drive | Florham Park, NJ 07932

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We are a team of highly driven pharmaceutical professionals who are passionate about our mission to improve the lives of people suffering from gastrointestinal diseases.

## OUR LOCATIONS



### Florham Park, NJ

- Corporate Headquarters
- 20 miles from NYC



### Buffalo Grove, IL

- R&D Headquarters
- 25 miles from Chicago

## LEADERSHIP TEAM

### Terrie Curran

Chief Executive Officer

### Azmi Nabulsi, M.D., M.P.H.

Chief Operating Officer

### Martin Gilligan

Chief Commercial Officer

### Tom Harris

SVP, Regulatory Affairs

### Joe Hand

Chief Administrative Officer

### Eckhard Leifke, M.D., PhD

Chief Medical Officer

### Larry Miller

General Counsel

## OUR VALUES

Phathom's core values determine our PHATE

<b>P</b> Perseverance	With <b>hard work</b> and <b>determination</b> we overcome all obstacles
<b>H</b> Humble	We <b>put others first</b> , remain grounded, and let our work speak for itself
<b>A</b> Accountable	We are <b>reliable</b> and take <b>personal responsibility</b> in all that we do
<b>T</b> Transparent	We say what we mean and have <b>no hidden agendas</b> .
<b>E</b> Entrepreneurial	We are humble, agile, and <b>embrace innovation</b> .

## OUR PIPELINE

TARGET INDICATIONS	PHASE 1	PHASE 2	PHASE 3
<b>Vonoprazan + antibiotics</b>			
<b>H. pylori treatment</b>			
Dual therapy (vonoprazan + amoxicillin)			
<b>pHalcon</b>			
Triple therapy (vonoprazan + amoxicillin + clarithromycin)			
<b>Vonoprazan</b>			
<b>GERD/EE treatment</b>			
Healing of erosive esophagitis and relief of heartburn			
<b>pHalcon</b>			
Maintenance of healing of erosive esophagitis and relief of heartburn			
<b>GERD/NERD treatment</b>			
Treating heartburn associated with symptomatic non-erosive GERD (NERD)			
<b>pHalcon</b>			

\* Vonoprazan is a product candidate that is under clinical study and that has not been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of vonoprazan.

## PREVALENCE AND BURDEN OF ACID-RELATED DISORDERS REMAINS HIGH

### GERD


(Gastroesophageal Reflux Disease)

GERD is a common, chronic, recurring condition caused by the exposure of gastric acid from the stomach to the esophagus.

Over **65 million US patients** are living with GERD and it is estimated that approximately **2/3** of this population have **NERD**.

GERD patients with **persistent symptoms** typically undergo endoscopy and are diagnosed with having either **erosive esophagitis (EE)** or **non-erosive reflux disease (NERD)**.

Inadequate acid suppression can lead to poor mucosal healing and serious long-term effects. **Acid suppression** plays an important role in optimizing **GERD** treatment.



### H. pylori

(Helicobacter pylori Infection)

**H. pylori** is a common cause of chronic stomach lining infection. The bacterium infects **~50%** of the world and **36%** of the US population.

Chronic inflammation produced by **H. pylori infection**, causes patients to develop a range of pathologies including **peptic ulcer disease** and **gastric cancer**.

Studies found that **~1 in 5** patients treated for **H. pylori** will fail first line therapy when using standard clarithromycin triple therapy.



**Treatment** is recommended for all patients diagnosed with **H. pylori** infection. Anti-secretory agents **reduce gastric acid level** to increase **antibiotic stability** and **potency** against **H. pylori**.

## HISTORY OF GASTRIC ACID SUPPRESSION DRUGS

